Larimar Therapeutics, Inc.
For the period ended Jun 29, 2026. Filed Jun 29, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Jun 29, 2026 · Filed Jun 29, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Consistent Long-term Safety Profile
Consistent Long-term Safety Profile
Long-term daily dosing was generally well tolerated with 13 adults on treatment for 1 year, 7 for 18 months, and 3 for 2 years
10,000 doses of nomlabofusp have been administered in the OL study
Most common adverse events are local injection site reactions that were mild to moderate, decreased in frequency over time, and did not lead to any withdrawals from the study
21 participants discontinued
10 of 41 participants in OL study experienced anaphylaxis
9 had prior exposure to nomlabofusp, one had no prior exposure
All participants returned to their usual state of health after receiving standard treatment with no further sequelae
3 experienced generalized urticaria (no new occurrences since initiating antihistamine therapy)
8 withdrew (3 due to other adverse events)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.